| Literature DB >> 25424734 |
Raoul Orvieto1,2, Olga Dratviman-Storobinsky3,4, Daniel Lantsberg5,6, Jigal Haas7,8, Roy Mashiach9,10, Yoram Cohen11,12.
Abstract
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS), is characterized by marked ovarian enlargement and acute third space fluid sequestration that almost always develops after hCG administration or in early pregnancy. OHSS is similar to vascular leak syndrome (VLS), which may be attributable to the massive increase in systemic inflammatory cytokines. In the present pilot exploratory case series, we sought to evaluate interleukin (IL)-2 and suppressor of cytokine signaling (SOCS)-1 expressions in the peripheral blood mononuclear cells (PBMCs) of patients suffering from severe ovarian hypertimulation syndrome (OHSS), and to examine whether their expressions differ when compared to PBMCs originated from normal early pregnant women (without OHSS).Entities:
Mesh:
Substances:
Year: 2014 PMID: 25424734 PMCID: PMC4255649 DOI: 10.1186/s13048-014-0106-2
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Figure 1Amplification time for fluorescence detection and melting curve of PCR product. A: Melting curve (heat dissociation) analyses for IL-2 gene expression. One PCR product peak at 78°C visible for the target PCR. The negative control shows no visible PCR product. B: Melting curve of PCR product for SOCS-1 gene. The real time PCR specificity was determined by the dissociation temperature of PCR products. The single peak at 84°C corresponded to the specific PCR product of SOCS-1 gene. C–D: Quantification of IL-2 (C) and SOCS-1(D) genes, in OHSS patients compared to control. Subsequently the ΔCT for each sample was determined using the equation ΔCT = CTtarget gene – CThousekeeping gene. ΔCT = CT (IL-2) – CT (GAPDH) ΔCT = CT (SOCS-1) – CT (GAPDH).
Demographic and clinical characteristics of the study groups
|
|
|
| ||
|---|---|---|---|---|
| Age (years) | Mean + SE | 32.6 ± 2.3 | 36.6 ± 5.8 | ns |
| Median (range) | 33 (30–36) | 38 (27–41) | ||
| Parity | Mean + SE | 0.8 ± 1.3 | 0.6 ± 0.5 | ns |
| Median (range) | 0 (1–3) | 1 (0–1) | ||
| BMI (Kg/m2) | Mean + SE | 24.2 ± 5.7 | 24.5 ± 5.6 | ns |
| Median (range) | 24.9 (16.6-32.4) | 22.5 (19.7-34.7) | ||
|
| ns | |||
| PCO (%) | 1(20) | 1 (20) | ||
| Mechanical (%) | 1(20) | 0 (0) | ||
| Male factor (%) | 2(40) | 3 (60) | ||
| Unexplained (%) | 1(20) | 1 (20) | ||
| Serum estradiol level on day of hCG administration (pmol/L) | Mean + SE | 9292 ± 2464 | 4167 ± 2730 | <0.02 |
| Median (range) | 9336 (6589–11908) | 3645 (1153–8575) | ||
| Number of oocytes retrieved | Mean + SE | 15.8 ± 2.3 | 7.8 ± 3.9 | <0.002 |
| Median (range) | 16 (12–18) | 9 (2–12) | ||
| IL-2 mRNA levels | Mean + SE | 2.449 ± 0.255 | 1.043 ± 0.146 | <0.01 |
| Median (range) | 2.272 (1.915-3.403) | 1.0 (0.6-1.59) | ||
| SOCS-1 mRNA levels | Mean + SE | 0.541 ± 0.144 | 1.171 ± 0.423 | 0.22 |
| Median (range) | 0.425 (0.225-0.974) | 1.0 (0.285-2.821) |
Figure 2PBMCs IL-2 and SOCS-1 mRNA levels in the OHSS and control groups.